{
    "clinical_study": {
        "@rank": "159889", 
        "arm_group": {
            "arm_group_label": "AG-120", 
            "arm_group_type": "Experimental", 
            "description": "AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics,\n      pharmacodynamics and clinical activity of AG-120 in advanced solid tumors, including glioma,\n      that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase\n      where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum\n      tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study\n      is a dose expansion phase where three cohorts of patients will receive AG-120 to further\n      evaluate the safety, tolerability, and clinical activity of the MTD. Anticipated time on\n      study treatment is until disease progression or unacceptable toxicity occurs."
        }, 
        "brief_title": "Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cholangiocarcinoma", 
            "Chondrosarcoma", 
            "Glioma", 
            "Advanced Solid Tumors"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Chondrosarcoma", 
                "Glioma", 
                "Cholangiocarcinoma", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Subject must be \u226518 years of age.\n\n          2. Subjects must have histologically or cytologically confirmed advanced solid tumors,\n             including glioma, that have recurred or progressed following standard therapy, or\n             that have not responded to standard therapy.\n\n          3. Subjects must have documented IDH1 gene-mutated disease based on local test\n             evaluation.\n\n          4. Subject must have evaluable disease by RECIST v1.1 for subjects without glioma or by\n             RANO criteria for subjects with glioma.\n\n          5. Subjects must be amenable to serial peripheral blood sampling, urine sampling, and\n             biopsies during the study.\n\n          6. Subjects must have ECOG PS of 0 to 1.\n\n          7. Subjects must have expected survival of \u22653 months.\n\n          8. Subjects must have adequate bone marrow function as evidenced by absolute neutrophil\n             count \u22651.5 \u00d710^9/L; Hemoglobin >9 g/dL (Subjects are allowed to be transfused to this\n             level); Platelets \u226575 \u00d7 10^9/L\n\n          9. Subjects must have adequate hepatic function as evidenced by Serum total bilirubin\n             \u22641.5 \u00d7 upper limit of normal (ULN), unless considered due to Gilbert's disease or\n             disease involvement; Aspartate aminotransferase (AST), alanine aminotransferase\n             (ALT), and alkaline phosphatase (ALP) \u22642.5 \u00d7 ULN. For subjects with bone metastases\n             and/or suspected disease-related liver or biliary involvement, ALP must be \u22645 \u00d7 ULN.\n\n         10. Subjects must have adequate renal function as evidenced by Serum creatinine \u22642.0 \u00d7\n             ULN OR Creatinine clearance >40 mL/min based on the Cockroft-Gault glomerular\n             filtration rate (GFR)\n\n         11. Subjects must be recovered from any clinically relevant toxic effects of any prior\n             surgery, radiotherapy, or other therapy intended for the treatment of cancer.\n\n         12. Female subjects with reproductive potential must have a negative serum pregnancy test\n             within 7 days prior to the start of therapy. Subjects with reproductive potential are\n             defined as one who is biologically capable of becoming pregnant. Women of\n             childbearing potential as well as fertile men and their partners must agree to\n             abstain from sexual intercourse or to use an effective form of contraception during\n             the study and for 90 days (females and males) following the last dose of AG-120.\n\n        Key Exclusion Criteria:\n\n          1. Subjects who previously received AG-120.\n\n          2. Subjects who received systemic anticancer therapy or radiotherapy <21 days prior to\n             their first day of study drug administration.\n\n          3. Subjects who received an investigational agent <14 days prior to their first day of\n             study drug administration.\n\n          4. Subjects who are pregnant or breastfeeding.\n\n          5. Subjects with an active severe infection or with an unexplained fever >38.5\u00b0C during\n             screening visits or on their first day of study drug administration (at the\n             discretion of the Investigator, subjects with tumor fever may be enrolled).\n\n          6. Subjects with New York Heart Association (NYHA) Class III or IV congestive heart\n             failure or LVEF <40% by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan\n             within approximately 28 days of C1D1.\n\n          7. Subjects with a history of myocardial infarction within the last 6 months.\n\n          8. Subjects with known unstable or uncontrolled angina pectoris.\n\n          9. Subjects with a known history of severe and/or uncontrolled ventricular arrhythmias.\n\n         10. Subjects with heart-rate corrected QT (QTc) interval \u2265450 msec or with other factors\n             that increase the risk of QT prolongation or arrhythmic events.\n\n         11. Subjects taking medications that are known to prolong the QT interval.\n\n         12. Subjects with known infection with human immunodeficiency virus (HIV) or active\n             hepatitis B or C.\n\n         13. Subjects with brain metastases that are untreated, symptomatic, or require therapy to\n             control symptoms; or any radiation, surgery, or other therapy, including those used\n             to control symptoms, within 2 months of randomization. Subjects with glioma who are\n             on a stable, steroid-dosing regimen prior to screening MRI may be permitted to enroll\n             with Medical Monitor approval."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073994", 
            "org_study_id": "AG120-C-002"
        }, 
        "intervention": {
            "arm_group_label": "AG-120", 
            "description": "AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity", 
            "intervention_name": "AG-120", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "chondrosarcoma", 
            "cholangiocarcinoma", 
            "glioma", 
            "advanced solid tumors", 
            "IDH1", 
            "AG-120"
        ], 
        "lastchanged_date": "June 4, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85255"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90095"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48201"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94800"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation", 
        "overall_contact": {
            "email": "molly.prahl@agios.com", 
            "last_name": "Molly Prahl, RN", 
            "phone": "617.649.8635"
        }, 
        "overall_contact_backup": {
            "email": "sam.agresta@agios.com", 
            "last_name": "Sam Agresta, MD, MPH & TM", 
            "phone": "617.649.8621"
        }, 
        "overall_official": {
            "affiliation": "Agios Pharmaceuticals, Inc.", 
            "last_name": "Clinical Development", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9 (ANSM)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety/tolerability: incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks, on average"
            }, 
            {
                "measure": "Maximum Tolerated Dose/recommended Phase II dose of AG-120 in subjects with advanced solid tumors, including glioma", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks, on average"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073994"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dose Limiting Toxicities of AG-120 in subjects with advanced solid tumors, including glioma", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks, on average"
            }, 
            {
                "description": "Descriptive statistics will be used to summarize PK parameters for each dose group and, where appropriate, for the entire population. Such parameters will include max concentration (Cmax), time to maximum concentration (Tmax), AUC, elimination half-life.", 
                "measure": "Pharmacokinetics of AG-120 in subjects with advanced solid tumors, including glioma", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks, on average"
            }, 
            {
                "description": "PD parameters will be summarized using the following descriptive statistics: n, Mean, SD, CV%, Median, Min, and Max, GeoMean, and GeoCV%.\nPK/PD correlations between exposure to AG-120 and the extent of suppression of 2-HG will be explored using graphical display of data.", 
                "measure": "Pharmacodynamic relationship of AG-120 and 2-HG", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks, on average"
            }, 
            {
                "description": "The clinical activity of AG-120 will be evaluated by assessing response to treatment according to RECIST v1.1 for subjects without glioma or by modified RANO criteria for subjects with glioma", 
                "measure": "Clinical Activity associated with AG-120 in subjects with advanced solid tumors, including glioma", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 weeks, on average"
            }
        ], 
        "source": "Agios Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Agios Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}